Jasper Therapeutics, Inc. Logo

Jasper Therapeutics, Inc.

Develops mast cell-depleting antibody therapies for chronic diseases and stem cell transplants.

JSPR | US

Overview

Corporate Details

ISIN(s):
US4718712023 (+3 more)
LEI:
Country:
United States of America
Address:
2200 BRIDGE PKWY SUITE #102, 94065 REDWOOD CITY
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for mast cell-driven diseases and as a conditioning agent for hematopoietic stem cell transplantation. The company's lead product candidate is briquilimab, a targeted anti-KIT (CD117) monoclonal antibody designed to deplete mast cells. Jasper is evaluating briquilimab in clinical studies for the treatment of chronic immunological and inflammatory diseases, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma. The company's mission is to develop safer and more effective therapies for patients with serious chronic diseases by harnessing the power of mast cell depletion.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Jasper Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Jasper Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Jasper Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

SUHEUNG CO.,LTD. Logo
Global manufacturer of capsules and contract manufacturing for pharma/nutraceutical industries.
South Korea
008490
Sumitomo Pharma Co., Ltd. Logo
R&D pharma creating medicines for oncology, psychiatry & neurology, focusing on Japan & the US.
Japan
4506
Summit Therapeutics Inc. Logo
Advancing a Phase 3 bispecific antibody for lung cancer and other solid tumors.
United States of America
SMMT
SunBio, Inc. Logo
Develops biopharmaceuticals and devices like artificial blood using proprietary PEGylation technology.
South Korea
067370
Sunshine Biopharma Inc. Logo
Develops novel oncology/antiviral drugs and commercializes generic pharmaceuticals in Canada.
United States of America
SBFM
SUPERNUS PHARMACEUTICALS, INC. Logo
Develops and commercializes therapies for CNS diseases like epilepsy, migraine, and ADHD.
United States of America
SUPN
SUTRO BIOPHARMA, INC. Logo
Develops engineered cancer drugs like ADCs using a cell-free protein synthesis platform.
United States of America
STRO
Swedish Orphan Biovitrum Logo
Develops innovative therapies for rare diseases in haematology, immunology, and specialty care.
Sweden
SOBI
SymBio Pharmaceuticals Limited Logo
Acquires and commercializes specialty drugs for unmet needs in Japan and the Asia-Pacific region.
Japan
4582
SynAct Pharma Logo
Biotech developing oral therapies to resolve inflammation in diseases like rheumatoid arthritis.
Sweden
SYNACT

Talk to a Data Expert

Have a question? We'll get back to you promptly.